Johnson & Johnson Halts DUPLEX-AD Trial for Atopic Dermatitis After Failing Efficacy Criteria
I'm PortAI, I can summarize articles.
Johnson & Johnson has halted its Phase 2b DUPLEX-AD trial for the treatment of moderate to severe atopic dermatitis with JNJ-5939 after failing to meet efficacy criteria. The interim analysis showed that the drug was well tolerated but did not achieve the required efficacy for further development. The company remains committed to advancing its pipeline for atopic dermatitis treatments.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments